Trevena

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Trevena recently reported disappointing Q2 earnings that revealed they completely missed the Street's expectations and only pulled in ~$180K in revenue. The COVID-19 headwinds are slamming Trevena and the forecast does not appear to be clearing up. As a result, I believe investors need to be patient with TRVN.

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Trevena's (TRVN) CEO Carrie Bourdow on Q2 2021 Results - Earnings Call Transcript

Trevena (TRVN) delivered earnings and revenue surprises of -12.50% and -85.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Trevena (TRVN) Reports Q2 Loss, Misses Revenue Estimates

Shares of Trevena (NASDAQ:TRVN) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 50.00% over the past year to ($0.09), which missed the estimate of ($0.07).

Trevena: Q2 Earnings Insights

Company reaffirms YE goal of 100 formulary wins

Trevena Reports Second Quarter 2021 Results

Exploratory analysis shows OLINVYK treated patients are ~50% less likely to experience an AE compared to morphine patients at equivalent levels of analgesia Exploratory analysis shows OLINVYK treated patients are ~50% less likely to experience an AE compared to morphine patients at equivalent levels of analgesia

Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy

Company to host conference call on Thursday, August 12th, 2021 at 8:00 a.m. ET Company to host conference call on Thursday, August 12th, 2021 at 8:00 a.m. ET

Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021

TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medical Center (VUMC) TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medical Center (VUMC)

Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19

Glass Lewis and Institutional Shareholder Services (ISS) independently recommend that Trevena shareholders vote “FOR” proposals to approve a Reverse Stock Split and concurrent Authorized Share Reduction Glass Lewis and Institutional Shareholder Services (ISS) independently recommend that Trevena shareholders vote “FOR” proposals to approve a Reverse Stock Split and concurrent Authorized Share Reduction

Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote “For” All Proposals Ahead of Special Meeting of Stockholders

Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care

Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research

Nhwa is conducting and funding this study to support NDA regulatory filing in China

Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical

-- Study is evaluating the role of age and weight in a comparative analysis of the effect of OLINVYK and morphine on respiratory function

Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects

Trevena (TRVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Trevena (TRVN) Rating Upgrade to Buy

Trevena Inc (NASDAQ: TRVN) has announced that the National Institute on Drug Abuse (NIDA), part of the NIH, has resumed recruitment for its proof-of-concept study for TRV734. The Company has collaborated with NIDA to evaluate TRV734 as potential maintenance therapy for opioid use disorder.

Hit By The Pandemic, Trevena Restarts Opioid Use Disorder Program After More Than A Year

-- TRV734 reduced drug-seeking behavior in a preclinical model of relapse, suggesting its utility as a novel oral maintenance treatment for opioid use disorder

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care

Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021

OLINVYK, oliceridine, is Trevena's first approved drug and offers a compelling safety, efficacy, and economic profile versus IV morphine.

Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2021 Results - Earnings Call Transcript

Trevena Inc's (NASDAQ: TRVN) TRV027 has been selected for an NIH ACTIV trial in COVID-19 patients that will be dosed in ~300 COVID-19 patients. TRV027 combats disruption within the renin-angiotensin-aldosterone system (RAAS) by specifically binding to and rebalancing AT1 receptor activation, blocking the damaging pathway that leads to acute lung damage and abnormal blood clotting, while activating the cellular pathway that selectively targets reparative actions that improve lung function and promote anti-inflammatory effects.

Trevena's TRV027 To Be Tested In NIH-Funded COVID-19 Trial

The stock price of Trevena Inc (NASDAQ: TRVN) increased 2.82% (from $1.77 to $1.82) pre-market. This is why it happened.

TRVN Stock: 2.82% Increase (From $1.77 To $1.82) Pre-Market Explanation

-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS

Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial

-- Company reaffirms YE target of 100 formulary approvals for OLINVYK®

Trevena Reports First Quarter 2021 Results

Trevena: Taking A Systematic Approach With A Speculative Investment

The stock price of Trevena Inc (NASDAQ: TRVN) increased by over 5% pre-market. This is why it happened.

TRVN Stock: Over 5% Increase Pre-Market Explanation

Trevena Inc (NASDAQ: TRVN) has announced that its novel AT1 receptor-selective agonist, TRV027, has been selected for inclusion in an international Phase 2-Phase 3 trial in COVID-19 patients. The trial is being conducted and funded as part of REMAP-CAP, a global network of clinicians, institutions, and research facilities to evaluate treatments with the potential to reduce mortality, ICU use, and morbidity in severely ill patients with COVID-19.

News for Trevena Stock (TRVN)